Laurion Capital Management LP Purchases New Holdings in Arvinas Inc (ARVN)

Laurion Capital Management LP purchased a new stake in Arvinas Inc (NASDAQ:ARVN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 150,000 shares of the company’s stock, valued at approximately $2,531,000. Laurion Capital Management LP owned 0.47% of Arvinas as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Gilder Gagnon Howe & Co. LLC purchased a new position in Arvinas in the third quarter valued at approximately $129,000. Citadel Advisors LLC purchased a new position in Arvinas in the third quarter valued at approximately $463,000. Birchview Capital LP purchased a new position in Arvinas in the third quarter valued at approximately $506,000. Dean Capital Investments Management LLC purchased a new position in Arvinas in the third quarter valued at approximately $631,000. Finally, Monashee Investment Management LLC purchased a new position in Arvinas in the third quarter valued at approximately $2,024,000. Hedge funds and other institutional investors own 41.89% of the company’s stock.

Shares of NASDAQ:ARVN opened at $16.59 on Friday. Arvinas Inc has a 52-week low of $13.70 and a 52-week high of $21.25.

In other news, Director Bradley Albert Margus acquired 40,000 shares of the stock in a transaction on Monday, October 1st. The stock was bought at an average price of $16.00 per share, with a total value of $640,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sean A. Cassidy acquired 1,600 shares of the stock in a transaction on Monday, October 1st. The stock was purchased at an average cost of $16.00 per share, with a total value of $25,600.00. The disclosure for this purchase can be found here. Insiders acquired 354,100 shares of company stock valued at $5,665,600 in the last ninety days.

Several research analysts recently commented on the stock. Piper Jaffray Companies assumed coverage on shares of Arvinas in a report on Monday, October 22nd. They issued an “overweight” rating and a $23.00 price target on the stock. Goldman Sachs Group assumed coverage on shares of Arvinas in a report on Monday, October 22nd. They issued a “neutral” rating and a $17.00 price target on the stock. Finally, Citigroup assumed coverage on shares of Arvinas in a report on Monday, October 22nd. They issued a “buy” rating and a $21.00 price target on the stock.

WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/12/08/laurion-capital-management-lp-purchases-new-holdings-in-arvinas-inc-arvn.html.

Arvinas Company Profile

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer.

Read More: What is the LIBOR?

Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas Inc (NASDAQ:ARVN).

Institutional Ownership by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply